Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 14/20 | 0.52 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.44 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.44 |
| ▸ | AKT1 | P31749 | 1/20 | 0.41 |
| ▸ | AKT2 | P31751 | 1/20 | 0.41 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11929577 | 0.92 | SLC2A1 (0.55) | SLC2A1KCNK3KCNK9MTNR1B | |
| SCHEMBL11929578 | 0.86 | SLC2A1 (0.48) | SLC2A1KCNK3KCNK9 | |
| SCHEMBL11929575 | 0.83 | SLC2A1 (0.49) | SLC2A1MTNR1B | |
| SCHEMBL4672221 | 0.74 | MC4R (0.51) | SLC2A1 | |
| SCHEMBL1691367 | 0.72 | SLC2A1 (0.52) | SLC2A1MTNR1B | |
| SCHEMBL11929563 | 0.71 | SLC2A1 (0.47) | SLC2A1KCNK3KCNK9MTNR1B | |
| SCHEMBL12818971 | 0.68 | SLC2A1 (1.00) | SLC2A1KCNK3KCNK9 | |
| SCHEMBL4669886 | 0.68 | MTNR1B (0.47) | SLC2A1KCNK3KCNK9MTNR1B | |
| SCHEMBL11929606 | 0.68 | SLC2A1 (0.54) | SLC2A1KCNK3KCNK9AVPR1B | |
| SCHEMBL11929614 | 0.68 | SLC2A1 (0.43) | SLC2A1KCNK3KCNK9AKT1AKT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8236818-B2 | Substituted imidazopyridine derivatives as melanocortin-4 receptor antagonists | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2012-08-07 | — | — | US | disclosed |
| US-20100093697-A1 | Substituted Imidazopyridine Derivatives As Melanocortin-4 Receptor Antagonists | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2010-04-15 | — | — | US | disclosed |
| WO-2008116665-A1 | SUBSTITUTED IMIDAZOPYRIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR ANTAGONISTS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093697-A1 | Substituted Imidazopyridine Derivatives As Melanocortin-4 Receptor Antagonists | MC4R, MC3R, MC5R | SLC2A1 3850/4885KCNK3 2573/4885KCNK9 3373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.